H.C. Wainwright analyst Douglas Tsao maintained a Buy rating on Protagonist Therapeutics (PTGX) today and set a price target of $33.00. The company’s shares closed last Wednesday at $23.44, close to its 52-week high of $24.96.
According to TipRanks.com, Tsao is a 4-star analyst with an average return of 12.1% and a 52.2% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Crinetics Pharmaceuticals, Minerva Neurosciences, and Revance Therapeutics.
Protagonist Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $39.50, a 61.4% upside from current levels. In a report issued on December 7, BMO Capital also maintained a Buy rating on the stock with a $46.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $24.96 and a one-year low of $5.30. Currently, Protagonist Therapeutics has an average volume of 365.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of novel constrained peptide-based drug candidates that address significant unmet medical needs. The firm’s initial lead product candidates, PTG-100 and PTG-200, are being developed for moderate-to-severe ulcerative colitis and Crohn’s disease, respectively. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.
